Lipocine (NASDAQ:LPCN) Upgraded at Wall Street Zen

Posted by Francis Steltz on Jul 21st, 2026

Wall Street Zen upgraded shares of Lipocine (NASDAQ:LPCN – Free Report) from a sell rating to a hold rating in a research report report published on Saturday.

A number of other research analysts also recently issued reports on the company. HC Wainwright reissued a “neutral” rating on shares of Lipocine in a report on Monday, April 6th. Weiss Ratings cut shares of Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $15.00.

Get Our Latest Analysis on LPCN

Lipocine Stock Performance

Shares of LPCN opened at $2.15 on Friday. The business’s 50-day moving average is $2.30 and its two-hundred day moving average is $5.29. The company has a market capitalization of $17.72 million, a P/E ratio of -1.15 and a beta of 0.44. Lipocine has a fifty-two week low of $1.81 and a fifty-two week high of $12.37.

Lipocine (NASDAQ:LPCN – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.03). Lipocine had a negative net margin of 571.18% and a negative return on equity of 66.70%. The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.16 million. Analysts forecast that Lipocine will post -1.91 EPS for the current year.

Hedge Funds Weigh In On Lipocine

Institutional investors and hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP boosted its position in Lipocine by 57.5% during the first quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock worth $153,000 after purchasing an additional 6,982 shares in the last quarter. Ikarian Capital LLC purchased a new stake in shares of Lipocine in the fourth quarter valued at approximately $1,602,000. Boothbay Fund Management LLC purchased a new stake in shares of Lipocine in the fourth quarter valued at approximately $441,000. Jane Street Group LLC acquired a new position in shares of Lipocine during the 4th quarter worth approximately $85,000. Finally, Renaissance Technologies LLC raised its stake in shares of Lipocine by 3.6% during the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after buying an additional 1,300 shares during the period. Hedge funds and other institutional investors own 9.11% of the company’s stock.

About Lipocine

(Get Free Report)

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.